FDA approves new osteoporosis drug for postmenopausal women

The US Food and Drug Administration has approved a new treatment for osteoporosis in postmenopausal women who are at high risk of bone fractures.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news

Related Links:

Publication date: July 2019Source: Biomedicine &Pharmacotherapy, Volume 115Author(s): Yanhai Xi, Tingwang Jiang, Jiangming Yu, Mintao Xue, Ning Xu, Jiankun Wen, Weiheng Wang, Hailong He, Xiaojian YeAbstractThe aim of the present study was to investigate the anti-osteoporotic activity of Baohuoside I, an active component of Herba Epimedii. Effects of Baohuoside I on the differentiation of BMSCs and the formation of adipocytes were evaluated using alkaline phosphatase staining and methylene blue staining method, respectively. Osteoporosis model was established in ovariectomized rats prior to the measurement of the serum ...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
In this study, rBMSCs were treated with medium (CON), PTE, osteogenic induction (OI), and a combination of PTE and OI (PTE+OI) over a 21-day period. We found that PTE significantly promoted rBMSCs osteogenic differentiation and mineralisation after 21 days of culturing. Moreover, PTE+OI further enhanced the differentiation and mineralisation process. PTE upregulated STE20, IGF1R, and p38 MAPK mRNA expression and downregulated TRAF6 mRNA expression. The extracts inhibited TRAF6 protein expression and promoted STE20, IGF1R, and phosphorylated p38 MAPK protein expression. Our results imply that PTE promotes the proliferation ...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
In this study, we treated egg-laying hens with DA, screened for key mRNAs and lncRNAs related to immune regulation using transcriptome technology, and performed cell experiments to explore the specific molecular biological mechanisms underlying the regulation of immune responses by lncRNAs. Materials and Methods Materials The DA used in this study was synthetically produced by the Kai Meng Co. (Xi An, Shanxi, China) Chemical Plant with a purity of 99.9%. Feeding Experimental Design and Bird Management The experimental animal procedures were approved by the China Agricultural University Animal Care and Use Committee (B...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusion Figure 4 shows that the 27 different molecular defects within the ALB so far reported to cause CAA are located in ten different exons (1, 3, 4, 5, 7, 8, 9, 10, 11, and 12) and in seven different introns (1, 2, 3, 6, 10, 11, and 12) (The Albumin Website, 2018; Caridi et al., 2019). Variations in the last two coding exons (13 and 14) would probably cause the presence of a circulating C-terminal variant of the protein and not CAA. The first twelve exons of ALB, with the exception of the two shortest, exons 2 and 6, were reported to contain at least one molecular defect resulting in CAA (The Albumin Website, 2018; ...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Conditions:   Osteoporosis;   Osteopenia Intervention:   Other: No intervention would be taken Sponsor:   Peking Union Medical College Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Amgen (NASDAQ: AMGN) announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was approved by the U.S. Food and Drug Administration (FDA) on April 9, 2019, for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news
In this study, the multivariate linear mixed model (LMM) was used to calculate the P-value to determine interesting SNPs at each time point using GEMMA software v0.97 (Zhou and Stephens, 2014). Growth data from both untreated and vancomycin-treated group formed the bivariate phenotype, which differs hugely from the univariate phenotype. Therefore, LMM developed for univariate phenotype cannot be applied to analyze correlated phenotype directly; methods allowing LMM algorithm specific to multivariate and correlated phenotype [multivariate LMMs (mvLMMs)] are in urgent need. GEMMA software could extend a standard LMM to mvLMM...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
AbstractPurpose of the ReviewVitamins play important roles in bone health, and vitamin supplementation has been recommended to prevent osteoporosis and to reduce fracture risk in the elderly. However, the benefits of vitamin intake for bone health are still controversial. The aim of the review is to examine the relationship between vitamins and bone health and how vitamins function in osteoblasts and osteoclasts.Recent FindingsA broad literature search with the PubMed database was performed. The results of human clinical studies are inconsistent due to differences in the study design, race, genetic factors, and the populat...
Source: Current Oral Health Reports - Category: Dentistry Source Type: research
Influence of Habitual Physical Behavior – Sleeping, Sedentarism, Physical Activity – On Bone Health in Community-Dwelling Older People Gladys Onambele-Pearson1*, Jorgen Wullems1,2, Conor Doody1, Declan Ryan1,3, Christopher Morse1 and Hans Degens4,5,6 1Department of Exercise and Sport Science, Manchester Metropolitan University, Manchester, United Kingdom 2Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium 3Faculty of Health and Society, University of Northampton, Northampton, United Kingdom 4School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom 5In...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
ConclusionsOur study extends the previous knowledge of reduced fracture risk of thiazides to persons with AD, a population with significantly increased background risk of fractures.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research
More News: Food and Drug Administration (FDA) | Health | Orthopaedics | Osteoporosis | Women